These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34622222)

  • 1. CombiFlow: Flow cytometry-based identification and characterization of genetically and functionally distinct AML subclones.
    Houtsma R; Hogeling SM; Schuringa JJ
    STAR Protoc; 2021 Dec; 2(4):100864. PubMed ID: 34622222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CombiFlow: combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones.
    Houtsma R; van der Meer NK; Meijer K; Morsink LM; Hogeling SM; Woolthuis CM; Ammatuna E; Nijk MT; de Boer B; Huls G; Mulder AB; Schuringa JJ
    Blood Adv; 2022 Apr; 6(7):2129-2143. PubMed ID: 34543390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.
    Wood BL
    Curr Protoc Cytom; 2020 Jun; 93(1):e73. PubMed ID: 32311834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
    Zeijlemaker W; Kelder A; Cloos J; Schuurhuis GJ
    Curr Protoc Cytom; 2019 Dec; 91(1):e66. PubMed ID: 31763792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-Cell Mass Cytometry of Acute Myeloid Leukemia and Leukemia Stem/Progenitor Cells.
    Zeng Z; Konopleva M; Andreeff M
    Methods Mol Biol; 2017; 1633():75-86. PubMed ID: 28735481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones.
    de Boer B; Prick J; Pruis MG; Keane P; Imperato MR; Jaques J; Brouwers-Vos AZ; Hogeling SM; Woolthuis CM; Nijk MT; Diepstra A; Wandinger S; Versele M; Attar RM; Cockerill PN; Huls G; Vellenga E; Mulder AB; Bonifer C; Schuringa JJ
    Cancer Cell; 2018 Oct; 34(4):674-689.e8. PubMed ID: 30245083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
    Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
    Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal evolution of acute myeloid leukemia from diagnosis to relapse.
    Vosberg S; Greif PA
    Genes Chromosomes Cancer; 2019 Dec; 58(12):839-849. PubMed ID: 31478278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Leukemia stem cell and clonal evolution].
    Yoshimi A; Kurokawa M
    Nihon Rinsho; 2014 Jun; 72(6):1012-7. PubMed ID: 25016797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia?
    Xu J; Jorgensen JL; Wang SA
    Clin Lab Med; 2017 Dec; 37(4):787-802. PubMed ID: 29128069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
    Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
    Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enriching for human acute myeloid leukemia stem cells using reactive oxygen species-based cell sorting.
    Stevens BM; O'Brien C; Jordan CT; Jones CL
    STAR Protoc; 2021 Mar; 2(1):100248. PubMed ID: 33437968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
    Deng DX; Zhu HH; Liu YR; Chang YJ; Ruan GR; Jia JS; Jiang H; Jiang Q; Zhao XS; Huang XJ
    Leuk Lymphoma; 2019 Sep; 60(9):2181-2189. PubMed ID: 30773106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding.
    Maetzig T; Lieske A; Dörpmund N; Rothe M; Kleppa MJ; Dziadek V; Hassan JJ; Dahlke J; Borchert D; Schambach A
    Cells; 2022 Dec; 11(24):. PubMed ID: 36552809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
    Cui W; Zhang D; Cunningham MT; Tilzer L
    Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
    Fuda F; Chen W
    Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal dynamics in a single AML case tracked for 9 years reveals the complexity of leukemia progression.
    Kim T; Yoshida K; Kim YK; Tyndel MS; Park HJ; Choi SH; Ahn JS; Jung SH; Yang DH; Lee JJ; Kim HJ; Kong G; Ogawa S; Zhang Z; Kim HJ; Kim DD
    Leukemia; 2016 Feb; 30(2):295-302. PubMed ID: 26424407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Dominietto A
    Curr Opin Hematol; 2011 Nov; 18(6):381-7. PubMed ID: 21986564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis].
    Kern W; Haferlach T
    Med Klin (Munich); 2005 Jan; 100(1):54-9. PubMed ID: 15654545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.